Clinical trial
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With…
NCT05630807 · GlaxoSmithKline, Industry · Active, not recruiting
Key facts
| NCT number | NCT05630807 |
|---|---|
| Title | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) |
| Official title | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1) |
| Acronym | B-Well 1 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B, Hepatitis B, Chronic |
| Intervention type | Drug, Other |
| Interventions | Bepirovirsen, Placebo |
| Enrollment | 981 |
| Start date | Dec 7, 2022 |
| Primary completion | Nov 11, 2025 |
| Completion | May 5, 2026 |
| First posted | Nov 30, 2022 |
| Last update posted | Dec 15, 2025 |
| Countries | Argentina, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hong Kong, Hungary, India, Italy and 14 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: